SurePath™ Imaging Pap and HPV mRNA E6/E7
Use
Liquid‑based Pap testing (SurePath™ Imaging Pap) combined with HPV mRNA E6/E7 testing is intended for cervical cancer screening by identifying cytologic abnormalities and the presence of active high‑risk HPV infection (E6/E7 mRNA). Co‑testing improves detection of pre‑cancerous lesions compared to either test alone.
Special Instructions
Not provided.
Limitations
Not provided.
Methodology
Other
Biomarkers
Result Turnaround Time
Not provided.
Related Documents
For more information, please review the documents below
Specimen
Tissue (Unknown)
Volume
Not provided
Minimum Volume
Not provided
Container
SurePath™ preservative fluid vial
Collection Instructions
Collect cervical sampling with Cytobrush Plus GT (endocervical brush) and PapPerfect® plastic spatula; drop both detachable heads into SurePath™ vial; tighten cap; send at room temperature.
Causes for Rejection
Unlabeled vial; leakage; mismatch between patient name on vial and requisition; SurePath™ vial without collection device head(s).
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 4 weeks (Pap), 14 days (CT/NG stability not directly applicable) |
| Refrigerated | 6 months (Pap) |
Other tests from different labs that may be relevant